Key result
A strategy relying solely on remote monitoring without scheduled in-office visits showed no difference in major adverse cardiac events, while reducing in-office visits by almost 80%.
Answers are grounded in this paper and cite their sources.
This editorial refers to ‘Safety and efficiency of a common and simplified protocol for pacemaker and defibrillator surveillance based on remote monitoring only: a long-term randomized trial (RM-ALONE)’†, by F.J. García-Fernández et al., on page 1837. Cardiac implantable electronic devices, in particular cardiac pacemakers and implantable cardioverter defibrillators (ICDs), have evolved into a main pillar of treatment for arrhythmias. Regular control of device function is crucial in order to detect malfunction, evaluate events that are stored in the memory of these devices, and adapt the patient’s treatment. Novel technologies providing remote access to the devices allow a remote device monitoring with regular transmission of data to a central unit. These data are then readily available to the healthcare professionals. Several investigations have confirmed the feasibility of remote monitoring and demonstrated the potential for a significant reduction in patient visits and, consequently, utilization of healthcare resources1 and associated costs.2 Following this, remote monitoring combined with in-person evaluation has been recommended as standard for device follow-up.3 On top of these benefits, several studies have reported a significant reduction of hard clinical endpoints including total mortality as a result of remote monitoring.4 , 5 In contrast, other studies have failed to show such benefits,6 and the potential benefits of remote monitoring with the aim of reduction of clinical endpoints continue to be a subject of intense debate.7 , 8 Several factors have been proposed as potential modifiers of the effect of remote monitoring9 and consequently as an explanation for the discrepant results (Figure 1). In particular, a daily transmission of data (that does not have an impact on battery longevity10) and a pre-defined response pathway to alerts are considered crucial for achieving measurable effects. The elements of the telemonitoring cycle and factors that may jeopardize the benefit of telemonitoring (from Hindricks et al.9) In this issue of the European Heart Journal, García-Fernández and co-workers report the results of a randomized study on remote monitoring in patients with cardiac pacemakers or ICDs.11 Patients were randomized to either a strategy of remote monitoring with daily transmission of data combined with a remote interrogation every 6 months (without any scheduled in-office evaluations) or to a strategy of remote monitoring with daily transmission of data combined with in-office visits every 6 months. The primary endpoint was the rate of major adverse cardiac events; secondary endpoints included the numbers of in-office follow-ups and the workload of healthcare professionals. The study showed no difference in the primary endpoint, i.e. the rate of major adverse cardiac events, whereas there was a marked reduction by almost 80% of in-office visits (excluding the first and last visit) that was driven by a decrease in scheduled visits. Reassuringly, the number of unscheduled visits did not differ significantly. Furthermore, there was also a significant decrease in the median staff workload by approximately one-third from 140 to 93 min. The study has several interesting aspects that differentiate it from other studies in the field of remote monitoring. First, this is not a study comparing remote monitoring with routine practice of in-office interrogations in order to detect the clinical benefit of remote monitoring. It is rather a study investigating the safety of a strategy relying solely on remote monitoring. Indeed, remote monitoring was applied in both arms. The difference between the two arms was that in the home monitoring arm, scheduled in-office visits were completely abandoned. This is the first study reporting such a comparison in a randomized fashion and with a sufficient follow-up duration. In this context, it is important to note that approximately half of the pacemaker patients were pacemaker dependent. Similarly, among the ICD carriers, there was a high percentage of patients with a secondary prevention indication considered to be at higher risk of shocks and consequently at higher risk in case of undetected device malfunction. These patients were frequently excluded from previous trials. Thus, the main message of the study is obviously that a strategy relying solely on remote monitoring is safe even in patients considered to be at high risk in the case of undetected device malfunction. Secondly, it provides very interesting data on the effect of remote monitoring on healthcare utilization. The authors correctly emphasize the significant reduction of utilization of healthcare resources as well as of time spent per patient and in total by the healthcare personnel in the arm that was only remotely monitored. Nevertheless, we have to keep in mind that remote monitoring still consumes a considerable amount of time. This is obvious when comparing the reduction rates of total visits by almost 80% with the much smaller, albeit still evident, and significant decrease by ∼33% of total time spent by the healthcare professionals. This difference means that the healthcare personnel spend significant time for evaluation of the transmitted data and management of alerts. This time is not so obviously visible as regular in-office visits and becomes particularly important in the light of varying and frequently absent reimbursement strategies across different European countries. Not surprisingly, a survey of the European Heart Rhythm Association has identified reimbursement as one of the barriers to implementation of the technique.12 Regarding the effect of remote monitoring on hard clinical endpoints, the findings of the study are not surprising. Considering the fact that in both arms daily transmission of data was performed using the same platform and assuming that the reaction pathways to alerts were the same in the two arms, one would not expect a significant difference in hard clinical endpoints. In conclusion, the study by García-Fernández and co-workers provides an additional piece of evidence for the safety of patients that are remotely monitored. Remote monitoring technologies have a great potential for significant savings in healthcare resources provided that these follow-up techniques are reimbursed in a way that is adequate considering the significant amount of time required by the healthcare professionals. What will be the next steps for a potentially even more beneficial implementation of remote monitoring technology in the healthcare system? Most probably, this will involve the connection of remote monitoring data that are automatically transmitted by the device with automatic algorithms supported by artificial intelligence. Indeed, such systems have already been developed and proved to be functionally reliable: based on the algorithms applied in the InTime trial that showed significant benefits of multiparameter remote monitoring, automatic decision trees have been developed that would allow an automatic activation of treatment pathways whenever individually set alert margins are crossed. Such SOPs automatically activated and signed off by medical staff would allow an even faster response time, with precise and personalized treatment recommendations based on individual data sets for both rhythm and heart failure events. In addition, such systems may also further reduce healthcare costs. However, needless to say, clinical trials are needed to evaluate the effects of artificial intelligence in this setting and provide proof of safety and medical benefits.5 Conflicts of interest: G.H. and N.D. report research grants from Abbott, Biotronik, Boston Scientific, and Medtronic to their institution without personal financial benefits. The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Hindricks et al. (2019) conducted an editorial in Cardiac arrhythmias requiring pacemakers or ICDs. Remote monitoring alone (daily transmission with remote interrogation every 6 months) vs. Remote monitoring with daily transmission combined with in-office visits every 6 months was evaluated on Rate of major adverse cardiac events. A strategy relying solely on remote monitoring without scheduled in-office visits showed no difference in major adverse cardiac events, while reducing in-office visits by almost 80%.
Synapse has enriched 10 related papers. Consider them for comparative context: